Intrinsiqq
DocCheck AG logo

DocCheck AG Quality Score

AJ91.XETR

⊜ Compare
Quality57

Growth is the primary weakness (avg 0/100). Valuation is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
10.0x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
80/100
23.8x

20–25x, moderate cash flow premium

Revenue Growth
0/100
-3.2%

Below 2%, essentially flat

Cash Flow Growth
0/100
-36.9%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
60/100
0.8%

Mild dilution under 2%

Margin Trend
90/100
+1.2pp

Expanded 1–3pp, steady progress

Capital Structure
100/100
-€14M

Net cash position, no leverage concern

2022
€16.0M
€7.00M
2023
€18.0M
€6.00M
2024
€21.0M
€5.00M
2025
€19.0M
€4.00M
CashDebt
Return on Capital
60/100
12.3%

10–15%, respectable returns

Customize WeightsPremiumUpgrade

DocCheck (AJ91.XETR) quality: score, margins and returns

DocCheck (AJ91.XETR) scores 57/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 15.9% operating margins and 12.3% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is DocCheck (AJ91.XETR) a high-quality business?+

DocCheck scores 57 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 15.9% operating margin and a 12.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does DocCheck's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from AJ91.XETR's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where DocCheck scores well and where it falls behind.

What is DocCheck's return on invested capital (ROIC)?+

DocCheck earns about 12.3% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to AJ91.XETR's margins and growth on this scorecard to judge durability.

How profitable is DocCheck?+

DocCheck runs an operating margin of about 15.9% and a net margin of about 9.6%. Revenue has grown at roughly -10.4% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on AJ91.XETR: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Health Information Services · Pick stocks to compare with AJ91.XETR

CompareIntrinsic value
7V0.XETRDarwin AG
€6.30-3.08%24
LIK.XETRLimes Schlosskliniken AG
€530.00+1.92%67
FYB.XETRFormycon AG
€18.68-1.68%10
V3V.XETRFamiCord AG
€2.68-3.94%39
M3V.XETRMeVis Medical Solutions AG
€19.90-0.50%48
GME.XETRGeratherm Medical AG
€2.13+0.00%47
AAQ1.XETRaap Implantate AG
€1.47+1.38%33
HPHA.XETRHeidelberg Pharma AG
€2.01-3.37%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AJ91.XETR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.